Biologics License Applications (BLAs)

A Biologics License Application (BLA) is the formal request a manufacturer submits to the FDA seeking permission to market a biologic product, including vaccines. The BLA represents the culmination of years of research, clinical trials, and manufacturing development.

What Must Be Submitted

A complete BLA must include comprehensive data in several categories:

• CMC (Chemistry, Manufacturing, Controls): Detailed manufacturing processes, facility information, product specifications, stability data
• Preclinical data: Animal studies demonstrating safety and immunogenicity
• Clinical data: Results from all phases of clinical trials
• Labeling: Package insert, patient package insert, medication guide
• Quality data: Batch records, validation studies, quality control tests

The Review Timeline

The FDA has statutory timeframes for BLA review:

• Standard review: 10 months from submission to FDA decision
• Priority review: 6 months for products addressing unmet medical needs
• Accelerated approval: For serious conditions based on surrogate endpoints
• Breakthrough therapy: Intensive FDA guidance during development

Facility Inspections

Before approval, FDA inspectors evaluate manufacturing facilities:

• Pre-license inspections: Verify manufacturing processes are in control
• CGMP compliance: Current Good Manufacturing Practice requirements
• Product testing: Review of quality control test results
• International facilities: FDA inspects foreign manufacturing sites

The Standard for Approval

Public Access to BLA Data

Much of the BLA data is publicly available:

• Drugs@FDA database: Searchable database of approved biologics
• Package inserts: Full prescribing information
• FDA review documents: Summary of FDA's scientific evaluation
• Clinical trial data: Results posted on ClinicalTrials.gov

Sources & Citations

• FDA: Biologics License Applications
• FDA: Drugs@FDA Database